title: Recent patents on oral combination drug delivery and formulations.
abstract: Oral combination drug delivery systems have been proven to be highly beneficial and vital in the treatment of several dreadful diseases such as cancer, HIV (AIDS) and tuberculosis. Further, pharmaceutical companies have often explored the strategy of combination drug therapy for treating diseases such as diabetes (Type 2), cardiovascular diseases, central nervous system (CNS) disorders, and for treating several other microbial infections. Patenting combination drug delivery systems and formulations has been proven to be very beneficial for the sustainment and growth of pharmaceutical industry. Several pharmaceutical companies have explored this opportunity in extending the life cycle of their blockbuster molecules, and providing additional sources of revenues when the new chemical entity (NCE) discovery is scarce. The article reviews some recent combination formulation patents and patent publications, particularly the US patents and patent applications, relevant to oral delivery of pharmaceuticals. Examples of some oral combination products on the US and worldwide market are presented. Patents and patent applications on combination oral formulations relevant to analgesics (including anti-inflammatory and antipyretics), cardiovascular system (CVS) products, antibacterial and antiviral, and central nervous system (CNS) products are briefly discussed.
authors.affiliation: Pharmaceutics International Inc., 10819 Gilroy Road, Hunt Valley, MD 21031, USA. phiremath@pharm-int.com
authors.forename: Praveen S
authors.initials: PS
authors.lastname: Hiremath
authors.forename: Shrikant A
authors.initials: SA
authors.lastname: Bhonsle
authors.forename: Sridhar
authors.initials: S
authors.lastname: Thumma
authors.forename: Viswatej
authors.initials: V
authors.lastname: Vemulapalli
mesh_terms: D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D058633:Antipyretics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002491:Central Nervous System Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004345:Drug Industry; D006801:Humans; D010330:Patents as Topic
chemical_list: D000700:Analgesics; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D058633:Antipyretics; D002317:Cardiovascular Agents; D002491:Central Nervous System Agents; D004338:Drug Combinations